Thursday, August 13, 2026
Rival's cystic fibrosis drug fails, Vertex shares gain
Sionna Therapeutics said on August 10 that its cystic fibrosis add-on candidate SION-719, designed to be paired with Vertex's Trikafta, missed the primary endpoint in its Phase 2a trial and halted the program. The failure removed one of the most closely watched competitive threats to Vertex's dominant CF franchise, and Vertex shares rose roughly 7-9% intraday on the news.
/ Sources
/ Related
- Vertex tops Q2 estimates, raises 2026 revenue guidanceTuesday, August 4, 2026
- Vertex pays AbCellera $28M upfront for autoimmune T-cell engagersFriday, July 31, 2026
- Vertex to buy Crinetics for ~$10B in largest-ever dealWednesday, July 8, 2026
- FDA expands Casgevy gene therapy to children as young as 2Sunday, July 5, 2026